Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years.
暂无分享,去创建一个
George Kitis | Katyna Borroto-Esoda | P. Marcellin | Z. Goodman | S. Lim | S. Chuck | M. Rizzetto | K. Borroto-Esoda | G. Kitis | Ting Chang | E Jenny Heathcote | Ting-Tsung Chang | Zachary Goodman | S. Arterburn | E. Heathcote | S. Hadziyannis | E. Heathcote | Steven L Chuck | Mario Rizzetto | Patrick Marcellin | Seng Gee Lim | Stephanos J Hadziyannis | Sarah Arterburn | Nicolaos C Tassopoulos | Jia Ma | Carol L Brosgart | C. Brosgart | N. Tassopoulos | Seng‐Gee Lim | Jia Ma
[1] E. Schiff,et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[2] D. Lavanchy,et al. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures , 2004, Journal of viral hepatitis.
[3] M. Wulfsohn,et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. , 2003, The New England journal of medicine.
[4] G. Fattovich,et al. Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis , 1998, American Journal of Gastroenterology.
[5] M. Wulfsohn,et al. 1141 Complete genotypic and phenotypic analyses of HBV mutations identified in HBEAG-negative chronic hepatitis B patients receiving 96 weeks of adefovir dipivoxil (ADV) , 2003 .
[6] C. Gibbs,et al. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks , 2002, Hepatology.
[7] A. Morabito,et al. A randomized, controlled trial of a 24‐month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum , 1997, Hepatology.
[8] E. Schiff,et al. Histological outcome during long-term lamivudine therapy. , 2003, Gastroenterology.
[9] H. Will,et al. Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[10] P. Marcellin,et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. , 2004, The New England journal of medicine.
[11] S. Hadziyannis,et al. The long-term outcome of interferon-α treated and untreated patients with HBeAg-negative chronic hepatitis B , 2001 .
[12] Ching-Lung Lai,et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. , 2006, The New England journal of medicine.
[13] A. Makris,et al. Interferon alfa-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis type B. , 1990, Journal of hepatology.
[14] Neil Kaplowitz,et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis , 1981, Hepatology.
[15] S. Hadziyannis,et al. Efficacy of long‐term lamivudine monotherapy in patients with hepatitis B e antigen–negative chronic hepatitis B , 2000, Hepatology.
[16] Rupert G. Miller,et al. Survival Analysis , 2022, The SAGE Encyclopedia of Research Design.
[17] J. Pawlotsky,et al. 483 Final analysis of virological outcomes and resistance during 5 years of adefovir dipivoxil monotherapy in HBeAg-negative patients , 2006 .
[18] T. Santantonio,et al. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. , 2000, Journal of hepatology.
[20] Graeme Currie,et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. , 2005, The New England journal of medicine.
[21] K. Ishak,et al. Histological grading and staging of chronic hepatitis. , 1995 .
[22] E. Brunt,et al. Grading and staging the histopathological lesions of chronic hepatitis: The Knodell histology activity index and beyond , 2000, Hepatology.
[23] Ching-Lung Lai,et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. , 2003, Gastroenterology.
[24] Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis , 1998 .
[25] Man-Fung Yuen,et al. Viral hepatitis B , 2003, The Lancet.
[26] D. Vassilopoulos,et al. Hepatitis B e antigen–negative chronic hepatitis B , 2001, Hepatology.